Newsbenzinga
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
· Published
Article summary
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…